Of these reported adverse reactions, muscle-associated adverse reactions suggestive of rhabdomyolysis (increased CPK levels, myalgia, myospasm, numbness, malaise, and weakness) accounted for a large proportion of the patients (21 out of 37). The gene discussed is PIK3C2A; the disease is Myalgia.